Cellectis introduces human iPS derived hepatocyte product
The hiPS-HEP, with homogeneity, a long life span of stable CYP activity and reproducibility, provides a range of in vitro applications such as drug discovery, toxicity testing and
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
The octreotide formulations incorporate Aegis’ Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection. The Intravail/ProTek excipients allow for non-invasive delivery